Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate
Roche has conducted its joint-largest deal of the year so far, licensing a clinical-stage UCN2 (urocortin-2) analog being…
Swiss flagship project harnesses AI and sensors for diabetes prevention
Type 2 diabetes generates high healthcare costs in Switzerland and causes significant suffering for those affected. A multidisciplinary…
Why Nestle removes all artificial colors by end of 2026
Nestle is set to become the first major global food company to entirely eliminate artificial colorings from its…
What’s next for Roche’s expensive obesity pipeline?
It’s been less than two years since Roche dove into the obesity space with its $2.7 billion acquisition…
Roche unveils strategy to become ‘top 3’ obesity company
Roche has set its sights on becoming a “top three” obesity company, according to the pharma’s long-awaited strategy…
Zealand’s Zupreme serves up to 10.7% mean weight loss
Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at 42 weeks…
Roche’s obesity ambition not reliant on one megablockbuster
When Roche unveiled its long-awaited obesity strategy yesterday, it included a bold goal of becoming one of the…
Roche commits $100M to keep its GLP-1 Structure sound
In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100…
Roche’s GLP1/GIP drug sees 22.5% weight loss, readies ph. 3 push
Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s…
ADA: Roche, Zealand make tolerability case for petrelintide
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma…
Roche CEO lists 3 reasons for sitting out Big Pharma deal spree
While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce…
Elevidys fallout hasn’t dented Roche’s hopes for gene therapies
The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the…